EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Efficacy of botulinum toxin type A administration within the current therapeutic algorithm for chronic anal fissure: study protocol for the prospective multicentre observational study FISURBOT-GECO6

Nuria Ortega-Torrecilla, Jorge Arredondo, Franco Marinello, Maria Luisa Reyes-Diaz, Carlos Cerdán, Oscar Cano-Valderrama, Tamara Fernández, Lidia Cristóbal, Teresa Calderón, Beatriz Martín-Pérez

Techniques in Coloproctology · 2026-12 · 30 (1)

DOI: 10.1007/s10151-026-03370-0 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Techniques in Coloproctology, online erschienen am 13.06.2026. Verfasst von Nuria Ortega-Torrecilla und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Hospital Universitari Vall d'Hebrón, Barcelona, Spain. Hauptthemen laut MEDLINE: Fissure in Ano, Botulinum Toxins, Type A, Neuromuscular Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de Navarra.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic anal fissure is a common, benign anorectal condition associated with impaired quality of life. Despite the availability of several therapeutic options, considerable variability persists in its management, particularly regarding the role of botulinum toxin type A administration within the current treatment algorithms. Although botulinum toxin type A injection is a widely used approach to achieve chemical sphincterotomy, its real-world efficacy and safety across different clinical scenarios remain insufficiently characterised.

Aim

Our objective is to evaluate the efficacy and safety of botulinum toxin type A injection for the treatment of chronic anal fissure after failure of topical therapy or lateral internal sphincterotomy in routine clinical practice settings by analysing the healing rate, continence outcomes and the need for subsequent surgical intervention in predefined clinical scenarios.

Methods

FISURBOT-GECO6 (0143–2024-OBS) is a national, multicentre, prospective, pragmatic observational study. Consecutive patients with chronic anal fissure in whom botulinum toxin treatment is recommended according to routine clinical practice are eligible. Patients will be classified into three clinical scenarios: (1) chronic anal fissure with sphincter hypertonia and no risk factors for anal incontinence after failure of topical therapy; (2) chronic anal fissure with recognised risk factors for anal incontinence after failure of topical therapy; and (3) chronic anal fissure persisting or recurring at least 12 weeks after lateral internal sphincterotomy. Botulinum toxin type A administered at a dose of 50 or 100 IU, according to routine practice. Patients will be evaluated at 1, 3 and 12 months after treatment. The primary outcome is clinical healing. Secondary outcomes are anal continence, procedure-related morbidity, need for repeat treatment or surgery and patient satisfaction. Expected relevance This study will provide prospective, real-world data on the efficacy and safety of botulinum toxin type A injection for chronic anal fissure management in clinically relevant scenarios. The results are expected to help clarify the role of this approach within current therapeutic algorithms and inform clinical decision-making in daily practice. Trial Sponsor Spanish Society of Coloproctology (AECP).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fissure in AnoBotulinum Toxins, Type ANeuromuscular AgentsHumansChronic DiseaseProspective StudiesAlgorithmsTreatment OutcomeMulticenter Studies as TopicObservational Studies as TopicMaleFemaleAdultAnal Canal

Stichwörter der Autor:innen

Anal fissureBotoxBotulinum toxin

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Surgery, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.
  • Department of Surgery, Clínica Universidad de Navarra. Av, Pío XII 36, 31008, Pamplona, Navarra, Spain. jarredon@unav.es.
  • Department of Surgery, Hospital Virgen del Rocío, Sevilla, Spain.
  • Department of Surgery, Hospital Universitario de La Princesa, Madrid, Spain.
  • Department of Surgery, Complejo Hospitalario Universitario de Vigo, Vigo, Spain.
  • Department of Surgery, Hospital Galdakao-Usansolo, Bilbao, Spain.

Förderung

  • Universidad de Navarra

Zitieren

APA

Ortega-Torrecilla, N., Arredondo, J., Marinello, F., Reyes-Diaz, M. L., Cerdán, C., Cano-Valderrama, O., Fernández, T., Cristóbal, L., Calderón, T., & Martín-Pérez, B. (2026). Efficacy of botulinum toxin type A administration within the current therapeutic algorithm for chronic anal fissure: study protocol for the prospective multicentre observational study FISURBOT-GECO6. Techniques in Coloproctology, 30(1). https://doi.org/10.1007/s10151-026-03370-0

Vancouver

Ortega-Torrecilla N, Arredondo J, Marinello F, Reyes-Diaz ML, Cerdán C, Cano-Valderrama O, et al. Efficacy of botulinum toxin type A administration within the current therapeutic algorithm for chronic anal fissure: study protocol for the prospective multicentre observational study FISURBOT-GECO6. Techniques in Coloproctology. 2026;30(1). doi:10.1007/s10151-026-03370-0

BibTeX
@article{OrtegaTorrecilla2026,
  author = {Ortega-Torrecilla, Nuria and Arredondo, Jorge and Marinello, Franco and Reyes-Diaz, Maria Luisa and Cerdán, Carlos and Cano-Valderrama, Oscar and Fernández, Tamara and Cristóbal, Lidia and Calderón, Teresa and Martín-Pérez, Beatriz},
  title = {Efficacy of botulinum toxin type A administration within the current therapeutic algorithm for chronic anal fissure: study protocol for the prospective multicentre observational study FISURBOT-GECO6},
  journal = {Techniques in Coloproctology},
  year = {2026},
  volume = {30},
  number = {1},
  doi = {10.1007/s10151-026-03370-0}
}
Kostenlos starten →